Povezanost dužine trajanja bolesti i primenjene terapije sa metaboličkim sindromom kod pacijenata obolelih od sistemskog eritemskog lupusa
Sažetak
Cilj rada: Ispitati uticaj dužine trajanja bolesti i primenjene terapije na ispoljavanje metaboličkog sindroma (MetS) kod bolesnika sa sistemskim eritemskim lupusom (SLE). Materijal i metode: Ispitano je 55 bolesnika (50 žena i 5 muškaraca) sa dijagnozom i 49 zdravih kontrola sličnih godina starosti. MetS je definisan prema modifikovanim NCEP-ATP III dijagnostičkim kriterijumima tako da je gojaznost predstavljena indeksom mase tela BMI>30. Rezultati: U grupi SLE bolesnika sa MetS je bilo 23 bolesnika (41,82%). U kontrolnoj grupi je bilo 10(20.4%) bolesnika koji su imali MetS. Bilo je značajno više ispitanika sa SLE koji su imali MetS u odnosu na kontrolnu grupu(p=0.04). Dužina trajanja bolesti u grupi sa MetS je bila značajno veća u odnosu na one bez MetS (15.35±10.26 vs 10.44±7.88, p=0.05). Ispitivanjem je potvrđeno da postoji značajna pozitivna korelacija (R=0.285,p=0.035) između trajanja bolesti i broja parametara MetS. U grupi bez MetSy je bilo statistički značajno više bolesnika koji su lečeni primenom antimalarika u monoterapiji. Nađeno je da su bolesnici sa MetS bili duže lečeni kortikosteroidnom terapijom u odnosu na one koji nisu imali MetS (153.57±103.34 vs 114.75±83.32,p=0.129). Zaključak: Učestalost javljanja MetS je direktno proporcionalna dužini trajanja SLE. Pokazano je da je statistički manji broj bolesnika sa MetS lečen resochinom u monoterapiji u odnosu na one bez MetS i da je duža upotreba KS povezana sa većom učestalošću MetS kod obolelih od SLE.
Reference
Mills JA. Systemic lupus erythematosus. N Engl J Med. 1994;330(26):1871-9.
https://doi.org/10.1056/NEJM199406303302608
Skaggs BJ, Hahn BH, McMahon M. Accelerated atherosclerosis in patients with SLE--mechanisms and management. Nat Rev Rheumatol. 2012;8(4):214-23.
https://doi.org/10.1038/nrrheum.2012.14
Bozeman, S.R., Hoaglin, D.C., Burton, T.M. et al. Predicting waist circumference from body mass index. BMC Med Res Methodol 12, 115 (2012).
https://doi.org/10.1186/1471-2288-12-115
Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009;2(5-6):231-7.
https://doi.org/10.1242/dmm.001180
Sun C, Qin W, Zhang YH,et al.Prevalence and risk of metabolic syndrome in patients with systemic lupus erythematosus: A meta-analysis. Int J Rheum Dis. 2017;20(8):917-928.
https://doi.org/10.1111/1756-185X.13153
Doria A, Shoenfeld Y, Wu R, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases 2003;62:1071-1077.
https://doi.org/10.1136/ard.62.11.1071
Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 ;64(8):2677-86.
https://doi.org/10.1002/art.34473
Mok,C.C. Metabolic syndrome and systemic lupus erythematosus: the connection. Expert Review of Clinical Immunology. 2019.
https://doi.org/10.1080/1744666X.2019.1620601
Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997 Mar 1;145(5):408-15.
https://doi.org/10.1093/oxfordjournals.aje.a009122
Munguia-Realpozo P, Mendoza-Pinto C, Sierra Benito C, et al. Systemic lupus erythematosus and hypertension. Autoimmun Rev. 2019; 18(10):102371.
https://doi.org/10.1016/j.autrev.2019.102371
Chan CT, Sobey CG, Lieu M, et al. Obligatory Role for B Cells in the Development of Angiotensin II-Dependent Hypertension. Hypertens (Dallas, Tex 1979). 2015; 66(5):1023-1033.
https://doi.org/10.1161/HYPERTENSIONAHA.115.05779
Szabó MZ, Szodoray P, Kiss E. Dyslipidemia in systemic lupus erythematosus. Immunol Res. 2017;65(2):543-550.
https://doi.org/10.1007/s12026-016-8892-9
Urowitz MB, Gladman D, Ibañez D, et al. Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort. Lupus. 2007;16(9):731-5.
https://doi.org/10.1177/0961203307081113
Svenungsson E, Fei GZ, Jensen-Urstad K, et al. TNF-alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus. 2003;12(6):454-61.
https://doi.org/10.1191/0961203303lu412oa
Apostolopoulos, D., and E.F. Morand. It hasn’t gone away: the problem of glucocorticoid use in lupus remains, Rheumatology, Volume 56, Issue suppl_1, April 2017, Pages i114–i122.
https://doi.org/10.1093/rheumatology/kew406
Petri M, Lakatta C, Magder L, et al. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med. 1994;96(3):254-9.
https://doi.org/10.1016/0002-9343(94)90151-1
Oeser A, Chung CP, Asanuma Y, et al. Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. Arthritis Rheum. 2005 ;52(11):3651-9.
https://doi.org/10.1002/art.21400
Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349(25):2399-406.
https://doi.org/10.1056/NEJMoa035471
Ruiz-Irastorza G, Martín-Iglesias D, Soto-Peleteiro A. Update on antimalarials and systemic lupus erythematosus. Curr Opin Rheumatol. 2020;32(6):572-582.
https://doi.org/10.1097/BOR.0000000000000743
Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus. 1996 ;5 Suppl 1:S16-22.